Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial

BACKGROUND: The efficacy and safety of chemotherapy strategies combining the multi-target receptor tyrosine kinase inhibitor in patients with advanced EGFR/ALK wild-type non-squamous non-small-cell lung cancer (nsq-NSCLC) are undetermined. We aimed to investigate the efficacy and safety of anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhen, Yang, Xiuli, Ma, Tianjiang, Yang, Qiumin, Zhang, Chenghui, Chen, Yunfang, Wang, Pengyuan, D’Incecco, Armida, Metro, Giulio, Uematsu, Shugo, Wang, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459624/
https://www.ncbi.nlm.nih.gov/pubmed/36090635
http://dx.doi.org/10.21037/tlcr-22-558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459624/
https://www.ncbi.nlm.nih.gov/pubmed/36090635
http://dx.doi.org/10.21037/tlcr-22-558

Ejemplares similares